SK chemicals Site Manager● SK Chemical, cell culture influenza vaccine takes
non-clinical test
SK Chemical (CEO and vice chairman Kim Chang Geun) announced on the 25th that they takes non-clinical test to animals in [cell culture influenza vaccine development project] a vaccine localization project.
Dr. Go Dong Gyu, Gyeongbuk Institute for Bio Industry for [Customized vaccine raw material production supporting project] said that “non-clinical test is taken after the completion of research and process development right before the commercialization to verify the effect before administering to patients.”
A spokesperson of SK Chemical Life Science Biz said that “by establishing cell culture vaccination technology and production plant we shall have import replacement effect and overseas progress foundation as well as national public health and vaccine independence.
The first ‘cell culture influenza vaccine production facility’ in Korea established in the SK Chemical Andong vaccine plant can promptly react when ▲unexpected epidemics spread. It also can be utilized as an emergency production facility when there is new influenza or saas. ▲ It is freed from external pollution such as swine flu as it does not need fertile egg, the essential for the existing vaccine production.
SK Chemical will complete non-clinical test this year and will carry out the 1st and 3rd clinical test in 2012. It is expected to release in 2014 to make it a successful own developed vaccine commodity.
Since its merger of Dongshin Pharmaceutical in 2001, it will be an opportunity to be recognized its R&D capacity and it will enhance its vaccine independence and global advancement.